CalciMedica, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
CalciMedica, Inc. (CALC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $705.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2024-03-28
- CalciMedica, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $705.00K, a 55.29% increase from fiscal 2022.
- CalciMedica, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $454.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2023-12-31 | $705.00K 10-K · filed 2024-03-28 |
| 2022-12-31 | $454.00K 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |